Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial.
OBJECTIVE
To investigate the association between the length of the polymorphic trinucleotide CAG microsatellite repeats in exon 1 of the AR gene and the risk of prostate cancer containing TMPRSS2:ETS fusion genes.


METHODS
This nested case-control study came from subjects enrolled in the Prostate Cancer Prevention Trial and included 195 biopsy-proven prostate cancer cases with a known TMPRSS2:ETS status and 1344 matched controls.


RESULTS
There was no association between the CAG repeat length and the risk of TMPRSS2:ETS-positive (odds ratio, 0.97; 95% confidence interval, 0.91-1.04) or TMPRSS2:ETS-negative prostate cancer (odds ratio, 1.04; 95% confidence interval, 0.97-1.11) and in patients with low- or high-grade disease.


CONCLUSIONS
Our findings suggested that AR CAG repeats are not associated with TMPRSS2:ETS formation in prostate cancer.
Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD. Electronic address: figgw@helix.nih.gov.
William D
WD
Figg
Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
Cindy H
CH
Chau
Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
Douglas K
DK
Price
SWOG Statistical Center, the Fred Hutchinson Cancer Research Center, Seattle, WA.
Cathee
C
Till
SWOG Statistical Center, the Fred Hutchinson Cancer Research Center, Seattle, WA.
Phyllis J
PJ
Goodman
Chonbuk National University Medical School, Jeonju, South Korea.
Yonggon
Y
Cho
Department of Pathology, University of Colorado Denver School of Medicine, Aurora, CO.
Marileila
M
Varella-Garcia
School of Pharmacy and Molecular Sciences, James Cook University, Townsville, Queensland, Australia.
Juergen K V
JK
Reichardt
SWOG Statistical Center, the Fred Hutchinson Cancer Research Center, Seattle, WA.
Catherine M
CM
Tangen
Department of Urology and Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX.
Robin J
RJ
Leach
Department of Pathology, University of Colorado Denver School of Medicine, Aurora, CO.
Adrie
A
van Bokhoven
Department of Urology and Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX.
Ian M
IM
Thompson
Department of Pathology, University of Colorado Denver School of Medicine, Aurora, CO.
M Scott
MS
Lucia
D016022:Case-Control Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000378:metabolism; D050783:Proto-Oncogene Proteins c-ets / Q000032:analysis / Q000235:genetics*; D011944:Receptors, Androgen / Q000235:genetics*; D012307:Risk Factors; D012697:Serine Endopeptidases / Q000032:analysis / Q000235:genetics*; D018911:Trinucleotide Repeats
C410798:AR protein, human; D050783:Proto-Oncogene Proteins c-ets; D011944:Receptors, Androgen; D012697:Serine Endopeptidases; C421305:TMPRSS2 protein, human